Asundexian Shows 26% Stroke Risk Reduction in Phase III
Dateline – New Orleans, USA, Feb. 5, 2026 — Bayer announced that its investigational oral Factor XIa inhibitor asundexian...
Factor XIa inhibitor
Advertisement
Bristol Myers Squibb Unveils New Long-Term and Real-World Data for Camzyos at AHA 2025
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
Advertisement
